Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

Inclusion Criteria:

Patients with multiple myeloma who demonstrate evidence of serologic relapse/progression while on lenalidomide maintenance given as part of first line therapy (including upfront high-dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT)) without symptomatic relapse/progression. Lenalidomide maintenance is defined as single agent lenalidomide therapy of any doses up to 10 mg PO daily for up to 28 days (28-day cycle).
Male or female patients aged ≥ 18 years old
Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
Measurable disease as outlined in protocol guidelines
Participants must meet laboratory criteria as outlined in protocol guidelines

Exclusion Criteria:

Prior Elotuzumab

Patients with clinical relapse/progression as per the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma defined as one or more of the following criteria:

Development of new soft tissue plasmacytomas or bone lesions (osteoporotic fractures do not constitute progression)
Definite increase in the size of existing plasmacytomas or bone lesions. A definite increase is defined as a 50% (and ≥1 cm) increase as measured serially of the measurable lesion
Hypercalcemia (>11 mg/dL);
Decrease in hemoglobin of ≥2 g/dL not related to therapy or other non-myeloma-related conditions;
Rise in serum creatinine by 2 mg/dL or more from the start of the therapy and attributable to myeloma
Hyperviscosity related to serum paraprotein
Women who are pregnant or breast feeding or women of childbearing potential (WOCBP) not using an effective method of birth control. Women of childbearing potential must have a negative serum pregnancy testing within 7 days prior to the administration of drug.
Male patients whose sexual partners are WOCBP not using effective birth control
Patients with a prior malignancy with in the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix)
Patients with known positivity for human immunodeficiency virus (HIV)) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Patients with a diagnosis of POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or plasma cell leukemia (> 2.0 × 10^9/L circulating plasma cells by standard differential)